Surreal illustration of arteries and pharmaceutical capsules, symbolizing polyarteritis nodosa treatment.

Adalimumab: A Ray of Hope for Hepatitis B-Negative Polyarteritis Nodosa?

Lena Kashyap monogram
Lena Kashyap in Health & Wellness October 2026 • 5 min read.

"Discover how adalimumab therapy offers a promising approach to managing the challenging symptoms and relapses of polyarteritis nodosa, especially in patients without hepatitis B."


Polyarteritis nodosa (PAN) is a rare and challenging form of systemic vasculitis that primarily affects medium- to small-sized arteries. Unlike some other types of vasculitis, PAN is typically not associated with anti-neutrophil cytoplasmic antibodies (ANCA). This distinction is important because it influences the diagnostic and treatment approaches for the condition.

Historically, PAN was a devastating disease with a rapidly progressive and often fatal outcome. However, the introduction of corticosteroids has significantly improved survival rates. The current therapeutic approach involves assessing the severity of the disease using a five-factor score (FFS). For patients without critical organ involvement (indicated by the FFS), corticosteroids alone are often sufficient. However, when critical organs such as the kidneys, gastrointestinal tract, or heart are affected, cyclophosphamide is added to the treatment regimen.

In cases where conventional treatments fail or the disease relapses, biologic agents have emerged as potential therapeutic options. Activated endothelial cells, resulting from tumor necrosis factor (TNF) stimulation, play a crucial role in the pathogenesis of PAN. These activated cells perpetuate inflammation by producing pro-inflammatory cytokines. This case report delves into the use of adalimumab (ADA), a TNF monoclonal antibody (mAb), in a patient experiencing a vasculitis relapse, highlighting its effectiveness in suppressing clinical activity and preventing disease flares over a 26-month follow-up period.

AI Search Multiple angles on this topic

Brazilian Community Life in Sweden

InterNations describes active Brazilian communities in Stockholm, Goteborg, Uppsala, and other Swedish locations, with regular social events helping newcomers adjust to Swedish life. In Stockholm, activities include dinners, outings to Umeå and Linköping, and other gatherings organized by community ambassadors. Forró Stockholm separately promotes Brazilian dance, music, and culture through a non-profit organization, while a Stockholm-focused study examines how Brazilian immigrants use information and communication technologies in connection with nostalgia.

Evidence Limitations

No subsection-specific sources were provided for standard approaches or accepted methods. Accordingly, no evidence-based conclusion about established treatment methods or their limitations can be drawn here. Any assessment of adalimumab for hepatitis B-negative polyarteritis nodosa would require direct clinical and methodological sources.

Online Community History

The supplied historical sources concern KASKUS, an Indonesian discussion forum described as a home for hobby communities and marketplace activity. One KASKUS post discusses Doodstream and notes that the platform lacked a video-search feature comparable to YouTube. The other supplied posts concern cultural or entertainment discussions rather than medical history, so they do not establish milestones or foundational discoveries related to polyarteritis nodosa or adalimumab.

The Case: Adalimumab's Impact on Vasculitis Relapse

Surreal illustration of arteries and pharmaceutical capsules, symbolizing polyarteritis nodosa treatment.

In August 2012, a 42-year-old Han Chinese man sought medical attention at the dermatology clinic of National Cheng Kung University Hospital. His symptoms included purpuric reticulate erythema and nodules on his lower extremities, which had been present for six months. A biopsy of one of the nodules revealed dense infiltrates composed of abundant neutrophils and lymphocytes surrounding a subcutaneous small artery. The presence of neutrophilic fibrin-platelet thrombus in the lumen was consistent with the histopathological findings of PAN.

Further examination revealed additional symptoms, including weight loss, diffuse myalgia, ankle arthralgia, and testicular pain. He was subsequently referred to the rheumatological clinic for further evaluation and management. Physical examinations confirmed swollen ankle joints and an enlarged, indurated right testis. Laboratory tests showed elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels, while hemogram data and creatinine levels were unremarkable. Urinalysis results were normal. Autoantibody testing, including ANCA, antinuclear antibody, lupus anticoagulant, and rheumatoid factor, yielded negative results. Testing for hepatitis B and C viral markers also came back negative. Chest X-ray, electrocardiogram, and abdominal and cardiac echography revealed no significant abnormalities.

  • Initial Treatment: High-dose corticosteroids (1 mg/kg/day prednisolone) were initiated, leading to clinical remission, and azathioprine (2 mg/kg/day) replaced the tapering doses of prednisolone.
  • Relapse: He experienced a relapse with recurrent weight loss, right ankle swelling, right testicular pain, and new-onset hypertension.
  • No Kidney Involvement: There was no proteinuria or hematuria, normal creatinine levels, and negative findings on renal angiography.
  • Adalimumab Intervention: Adalimumab 40mg biweekly subcutaneous injections were prescribed without other immunosuppressive agents.
  • Positive Outcomes: This resulted in the absence of ankle swelling and testicular pain. There were no disease flares or infection complications during the treatment period of 26 months.
AI Search Multiple angles on this topic

Research Evidence Gap

No subsection-specific sources were supplied for the latest research and reviews. The available material therefore does not support a reliable summary of current clinical studies, systematic reviews, or treatment findings. Direct medical literature would be needed to evaluate adalimumab in hepatitis B-negative polyarteritis nodosa.

Unresolved Counterarguments

No subsection-specific sources were provided for counterarguments, treatment failures, or negative findings. It is therefore not possible to identify supported objections to adalimumab from the supplied material. Any discussion of unsuccessful treatment, safety concerns, or competing explanations would require dedicated clinical sources.

A Nonmedical Comparison

The comparative sources describe Hotel Albuquerque at Old Town rather than medical treatments. They consistently present it as a landmark luxury hotel in Albuquerque's Old Town district, with restaurants, an outdoor swimming pool, wedding venues, and modern amenities influenced by Hispanic heritage. Its Junior Suites may include separate seating areas, city or Old Town views, and private balconies, but these hospitality features provide no valid basis for comparing adalimumab with other therapies.

Following discontinuation of ADA (due to financial constraints), a recurrent episode occurred. This was marked by bilateral ankle swelling, nodular lesions on the left leg, and severe aching pain without motor deficit over the right leg and foot. A nerve conduction examination confirmed peroneal and tibial neuropathy. High-dose corticosteroids were re-introduced, leading to improvement in arthritis and skin lesions. The patient's prednisolone dosages are gradually being decreased, with the addition of weekly methotrexate up to 25 mg. Cyclophosphamide is under consideration for his PAN-associated neuropathy during subsequent follow-up.

Future Directions in PAN Treatment

While this case report highlights the potential of adalimumab in controlling PAN, it's essential to recognize the need for further research. Large-scale randomized trials are necessary to ascertain the therapeutic regimens and clinical benefits of TNF antagonists in PAN. The successful experience reported in adult-onset patients, including those with gastrointestinal or renal involvement, underscores the potential of TNF antagonists. These findings open avenues for optimizing treatment strategies and improving outcomes for individuals with this challenging rheumatology disorder. Ultimately, with more extensive research, healthcare professionals can better tailor treatment approaches, offering renewed hope for those grappling with PAN.

AI Search Multiple angles on this topic

Evidence-Based Synthesis

No subsection-specific sources were supplied for synthesis or expert commentary. The provided sources are largely unrelated to hepatitis B-negative polyarteritis nodosa and do not support an expert judgment about adalimumab. A meaningful synthesis would require verified clinical evidence and specialist interpretation.

Uncertain Future Directions

The supplied future-outlook sources concern Summer Place Apartments rather than medical research. They state that rental rates, availability, deposits, and specials may change without notice, that lease terms vary, and that displayed square footage is approximate. These administrative details do not provide evidence about future directions for adalimumab or polyarteritis nodosa research.

A Sports Information Context

The broader-context sources focus on the Michigan Wolverines college football team. ESPN and CBS Sports provide scores, highlights, standings, news, statistics, and the 2026 season schedule, while College-Football-Results.com offers historical scores, records, schedules, and analytics. This material does not address healthcare access, systemic challenges, hepatitis B, polyarteritis nodosa, or biologic treatment.

Missing Patient-Centered Evidence

No subsection-specific sources were provided for patient experiences or real-world impact. The available material therefore cannot substantiate claims about symptoms, quality of life, treatment burden, or patient decision-making. Patient-centered conclusions would require relevant clinical, qualitative, or health-services research.

Adalimumab beside other reported PAN outcomes

The adalimumab account suggests possible disease control, but explicitly notes that TNF blockade has not had fully validated efficacy for PAN. Its selection in this case reflected the absence of autoantibodies and hepatitis B infection, rather than established comparative evidence.[1]

Other reported treatment outcomes provide context, not a direct comparison: an infliximab report described improvement in most of its patients, while a review found observational evidence favoring cyclophosphamide with high-dose glucocorticoids over glucocorticoids alone for severe PAN, with an estimate whose confidence interval was broad.[2] [3]

A guideline’s conditional grading of most recommendations reflects the limited evidence base; it does not itself validate or rule out adalimumab.[4]

What remains unresolved for adalimumab in PAN

  • Would symptom control with adalimumab be seen in other patients, or was this response specific to the reported individual?[1]
  • Does symptom control persist after adalimumab is discontinued, or can symptoms recur as in the reported episode?[1]

Sources

  1. Adalimumab therapy in hepatitis B virus-negative polyarteritis nodosa (pmc.ncbi.nlm.nih.gov)
  2. Infliximab for the treatment of refractory polyarteritis nodosa. (pubmed.ncbi.nlm.nih.gov)
  3. Polyarteritis Nodosa: A Systematic Review of Test Accuracy and Benefits and Harms of Common Treatments (pmc.ncbi.nlm.nih.gov)
  4. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. (acrjournals.onlinelibrary.wiley.com)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is polyarteritis nodosa (PAN), and how is it different from other types of vasculitis?

Polyarteritis nodosa (PAN) is a rare and challenging form of systemic vasculitis that primarily affects medium- to small-sized arteries. A key distinction of PAN is that it is typically not associated with anti-neutrophil cytoplasmic antibodies (ANCA), which are often found in other types of vasculitis. This difference affects the way doctors diagnose and treat the condition, as it helps them narrow down the possible causes and select the most appropriate therapies. The article focuses on PAN in the absence of hepatitis B, which adds another layer of specificity to the context.

2

What role do corticosteroids and cyclophosphamide play in the treatment of polyarteritis nodosa (PAN)?

Corticosteroids have historically improved the survival rates of patients with PAN. According to the article, the current approach assesses disease severity using a five-factor score (FFS). Patients without critical organ involvement are often treated with corticosteroids alone. If critical organs like the kidneys, gastrointestinal tract, or heart are affected, cyclophosphamide is added to the treatment plan. The choice of these medications depends on the severity of the disease and which organs are involved, aiming to reduce inflammation and prevent organ damage.

3

How did Adalimumab (ADA) help the patient with polyarteritis nodosa (PAN) in the case study?

In the case study, adalimumab (ADA), a TNF monoclonal antibody (mAb), was used to treat a patient experiencing a vasculitis relapse. The patient, a 42-year-old Han Chinese man, had symptoms including purpuric reticulate erythema, nodules, weight loss, and joint pain. After initial treatment with high-dose corticosteroids and azathioprine, he relapsed and was then treated with adalimumab 40mg biweekly. This treatment resulted in the absence of ankle swelling and testicular pain and prevented further disease flares for 26 months. This suggests that adalimumab was effective in suppressing clinical activity and controlling the relapse.

4

Why is TNF antagonist like Adalimumab (ADA) considered for the treatment of polyarteritis nodosa (PAN)?

TNF antagonists like adalimumab (ADA) are considered because activated endothelial cells play a key role in PAN. These cells, stimulated by tumor necrosis factor (TNF), perpetuate inflammation by producing pro-inflammatory cytokines. Adalimumab targets and blocks TNF, thereby reducing inflammation. In the case study, adalimumab helped to control vasculitis relapse, showing its potential in suppressing clinical activity and preventing disease flares. This approach offers a potential therapeutic option when conventional treatments fail or the disease relapses.

5

What are the implications of using Adalimumab (ADA) in treating polyarteritis nodosa (PAN), and what further research is needed?

The successful use of adalimumab (ADA) in the case study suggests that it can be effective in controlling PAN, specifically by suppressing clinical activity and preventing relapses. However, the article highlights the need for more research, including large-scale randomized trials, to confirm these benefits and determine the best treatment approaches. The use of ADA provides hope for managing PAN and may lead to better treatment strategies and outcomes for patients. The experience reported in adult-onset patients underscores the potential of TNF antagonists, opening avenues for optimizing treatment strategies for individuals with this challenging rheumatology disorder.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.